Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • API Reference

© 2026 Annolyse.

←Back to companies

GEN · NZX

General Capital (GEN)

Financials / Finance company•Covered: HY23 - HY26•7 published briefings

General Capital is an NZX-listed financials / finance company company with HY23 - HY26 of published result briefings.

Latest briefing

HY26 · Released 21 November 2025

PBT fell 31.8% on 19% revenue growth as costs and book outpaced earnings

Around NZ$0.6m of exceptional first-half costs pushed ROE to 3.4% from 5.5% even as total assets grew 47.2% to NZ$275.8m.

Market data

As at close
Close price
NZD 0.26
Market cap
$23.9m
Dividend yield
4.6%

as at close, 21 July 2026. Source: yfinance.

Sections⌄
  1. Snapshot
  2. Valuation
  3. Chat
  4. Longitudinal View
  5. Follow-through
  6. Archive
  7. Related Insights
  1. Snapshot
  2. Valuation
  3. Chat
  4. Longitudinal View
  5. Follow-through
  6. Archive
  7. Related Insights

Snapshot

Latest metrics

HY26, released 21 November 2025

← Swipe to view more
GEN latest metrics
MetricValueChange
Revenue$12.9m↑ +19.0%
NPAT$1m↓ -37.5%
Operating cash flow$2.8m↓ -81.6%
ROE %3.4%↓ -2.2pp
DPS0.3c↓ -39.6%
Payout ratio vs NPAT %19.2%↓ -77.3pp
PBT$1.5m↓ -31.8%
FCF pre-lease$2.8m—
Debtor days3Outside range highOutside range high debtor days. 3d; 3-period range 0d to 0d. Debtor days: 3.2 days, above normal range; 3-period mean 0.1 days, range 0.0 days-0.2 days.n/m
Total assets$275.8m↑ +47.2%

Source: latest published briefing (HY26, released 21 November 2025). Change compares against the prior equivalent period: HY25, released 22 November 2024.

Valuation

Valuation

A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.

Prices as at close, 21 July 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$23.9m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

10.87x

i

Recent market cap compared with trailing earnings.

EPS

0.02

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not meaningful without positive comparable earnings growth.

EV/EBITDA

Not available

i

Not useful for this reporting shape.

P/FCF

Not available

i

Not available for this company right now.

P/B

0.8x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

4.6%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Price history

Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.

Share price

Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.

↗
Loading chart...

P/E over time

Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.

↗
Loading chart...

Chat

Ask about GEN

Ask follow-up questions about General Capital's latest result and company history.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about GEN

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Longitudinal view

Performance over time

The latest period is shown first.

← Swipe to view more
GEN metric history
MetricHY266 MONTHS21 November 2025FY2512 MONTHS26 May 2025HY256 MONTHS22 November 2024FY2412 MONTHS27 May 2024HY246 MONTHS28 November 2023FY2312 MONTHS29 May 2023HY236 MONTHS29 November 2022Trend
Revenue$12.9m$22.6m$10.8m$17.2m$8.1m$13.7m$3.5m
Chart
Revenue growth %19.0%31.8%38.6%Outside range highOutside range high revenue growth. 38.6%; 3-period range 4.4% to 34.6%. Revenue growth: 38.6%, above normal range; 3-period mean 19.3%, range 4.4%-34.6%.25.3%34.6%-99.7%4.4%Outside range lowOutside range low revenue growth. 4.4%; 3-period range 19% to 38.6%. Revenue growth: 4.4%, below normal range; 3-period mean 30.7%, range 19.0%-38.6%.
Chart
  • HY25 Revenue growth %: Outside range high revenue growth. 38.6%; 3-period range 4.4% to 34.6%. Revenue growth: 38.6%, above normal range; 3-period mean 19.3%, range 4.4%-34.6%.
PBT$1.5m$3.9m$2.2m$3.6m$0m$3.3m$1.5m
Chart
PBT growth %-31.8%8.3%-99.9%-99.9%-100.0%n/m—
Chart
NPAT$1m$2.8m$1.6m$2.6m$0m$2.3m—
Chart
NPAT growth %-37.5%7.7%33.0%15.1%—73.7%—
Chart
Operating cash flow$2.8m$41.4m$15.3m$4.2m$9.9m-$3.4m$2.6m
Chart
FCF pre-lease$2.8m——$4m$9.9m-$3.5m$2.6m
Chart
FCF post-lease——————$2.6m
—
DPS0.3c0.4c0.6c————
Chart
Payout ratio vs NPAT %19.2%31.7%96.5%————
Chart
Annual payout ratio vs EPS %—31.7%—————
—
ROE %3.4%9.6%5.6%9.8%0.0%9.3%—
Chart
Net debt—$148.7m—————
—
Debtor days3Outside range highOutside range high debtor days. 3d; 3-period range 0d to 0d. Debtor days: 3.2 days, above normal range; 3-period mean 0.1 days, range 0.0 days-0.2 days.00—010Outside range lowOutside range low debtor days. 0d; 3-period range 0d to 3d. Debtor days: 0.0 days, below normal range; 3-period mean 1.1 days, range 0.0 days-3.2 days.
Chart
  • HY26 Debtor days: Outside range high debtor days. 3d; 3-period range 0d to 0d. Debtor days: 3.2 days, above normal range; 3-period mean 0.1 days, range 0.0 days-0.2 days.
Total assets$275.8m$218.2m$187.4m$163.3m$141.5m$136.1m$126.3m
Chart

Reference: annolyse.ai/companies/gen

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Filing-only history charts

These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.

Revenue

Reported revenue across covered periods.

↗
Loading chart...

Revenue growth

Like-period revenue growth where comparable.

↗
Loading chart...
  • HY23 GEN HY: Outside range low revenue growth. 4.4%; 3-period range 19% to 38.6%. Revenue growth: 4.4%, below normal range; 3-period mean 30.7%, range 19.0%-38.6%.
  • HY25 GEN HY: Outside range high revenue growth. 38.6%; 3-period range 4.4% to 34.6%. Revenue growth: 38.6%, above normal range; 3-period mean 19.3%, range 4.4%-34.6%.

NPAT

Statutory profit after tax.

↗
Loading chart...

Operating cash flow

Cash generated from operations.

↗
Loading chart...

FCF pre-lease

Operating cash flow less capex before leases.

↗
Loading chart...

FCF post-lease

Free cash flow after lease payments where available.

↗
Loading chart...

Full chartable metric set

Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.

ROE

Return on equity.

↗
Loading chart...

Net debt

Borrowings less cash; negative values indicate net cash.

↗
Loading chart...

DPS

Dividend per share declared for the period.

↗
Loading chart...

Payout ratio

Dividend payout against statutory NPAT.

↗
Loading chart...

Debtor days

Receivables days where the working-capital inputs are source-backed.

↗
Loading chart...
  • HY23 GEN HY: Outside range low debtor days. 0d; 3-period range 0d to 3d. Debtor days: 0.0 days, below normal range; 3-period mean 1.1 days, range 0.0 days-3.2 days.
  • HY26 GEN HY: Outside range high debtor days. 3d; 3-period range 0d to 0d. Debtor days: 3.2 days, above normal range; 3-period mean 0.1 days, range 0.0 days-0.2 days.

The setup & the reality

FY25 → HY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Current result now available

HY26 · Released 21 November 2025

Annolyse analysis published 22 April 2026

PBT fell 31.8% on 19% revenue growth as costs and book outpaced earnings

Around NZ$0.6m of exceptional first-half costs pushed ROE to 3.4% from 5.5% even as total assets grew 47.2% to NZ$275.8m.

Read latest briefing→

Historical setup

What FY25 said to watch

Previous analysisFY25·Result released26 May 2025·Annolyse analysis published22 April 2026

From Assets up 33.6% on funded growth, but ROE direction weakened

No forward targets, loan-book guidance, NIM disclosure or forward-work book is provided in the supplied materials. The HY25 half delivered 47.9% of full-year revenue but 56% of full-year NPAT, which implies a softer second-half earnings shape: roughly $1.2m of implied 2H NPAT against $1.6m in HY25, despite revenue lifting from $10.8m to $11.8m. This is consistent with acquisition-related transaction or integration costs absorbing margin in the back half, but the release does not isolate the driver.

Investors have no disclosed benchmark to test FY25 against. The release does not provide loan-book size, arrears rate, NIM, or provision coverage, all of which are needed to judge whether the larger balance sheet is translating into durable, risk-adjusted earnings.

Open questions

Open questions from FY25

  • What is the loan-book size, arrears rate, net interest margin and provision coverage at FY25 versus FY24, and how do these compare against the BB credit rating profile?
  • How much of FY25 revenue, segment result and NPAT was contributed by the acquired business, and what does an organic-only comparison look like?
  • Why did Research & Advisory turn loss-making, and is that a structural shift in that segment's economics or a one-period effect?
  • Why did the implied second-half NPAT step down despite second-half revenue being higher than HY25?
  • Is 0.98 cents per share intended as a steady-state annual policy, or will distributions scale with continued balance-sheet growth and earnings?

This briefing cannot assess whether the expanded loan book is being grown at adequate risk-adjusted returns, because net interest margin, arrears and impairment data are not disclosed in the supplied materials.

Archive

Briefing archive

Every published Annolyse briefing for this company appears here in reverse chronological order.

HY26 · Released 21 November 2025

PBT fell 31.8% on 19% revenue growth as costs and book outpaced earnings

Around NZ$0.6m of exceptional first-half costs pushed ROE to 3.4% from 5.5% even as total assets grew 47.2% to NZ$275.8m.

Read briefing→

FY25 · Released 26 May 2025

Assets up 33.6% on funded growth, but ROE direction weakened

Balance-sheet expansion outpaced earnings, and an in-year acquisition broadens segment mix and limits clean year-on-year comparison.

Read briefing→

HY25 · Released 22 November 2024

Maiden dividend sets payout at 96.5% of NPAT as revenue growth slows to 38.7%

Operating cash of NZ$15.3m easily funds the inaugural distribution, but revenue growth has slowed sharply from the company's recent baseline.

Read briefing→

FY24 · Released 27 May 2024

NPAT rose 17% but PBT only 7% as Finance segment profit fell

A lower tax rate and non-recurring prior-year items flattered headline growth while the dominant Finance segment's result declined.

Read briefing→

HY24 · Released 28 November 2023

Revenue up 29.7% but Finance segment result fell 16% year-on-year

PBT grew just 1.6% and NPAT growth of 15.8% relied on a lower tax charge as the dominant Finance segment's profitability contracted.

Read briefing→

FY23 · Released 29 May 2023

PBT up 77.1% but ROE eased to 9.3% as equity outpaced earnings

Equity grew 79.2% versus 68.4% NPAT growth, signalling capital raised to fund the loan book has yet to lift per-dollar returns.

Read briefing→

HY23 · Released 29 November 2022

PBT up 390.8% on 94.7% revenue growth as margin reached 43.5%

Operating leverage from a fast-scaling loan book quintupled PBT in a still-small finance company increasingly funded by term deposits.

Read briefing→

Related insights

Compare this company

The latest GEN metrics also appear in these cross-company views.

Insight

Revenue growth context

Revenue growth was 19.0% for this reporting period.

Open insight→

Insight

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 5.7pp.

Open insight→

Insight

Dividend coverage and payout pressure

Dividend payout versus NPAT is 19.2%.

Open insight→

Insight

ROE and capital efficiency

ROE was 3.4%, -2.1pp versus the prior comparable period.

Open insight→

Get notified when GEN publishes

Get the next General Capital result briefing and five-year history updates by email.